► Exosens completes the closing of the acquisition of Centronic, Leader in Radiation Detection Solutions
Mérignac, France and Croydon, United Kingdom – August, 1st 2024- Exosens announces the closing of the acquisition of UK-based Centronic, a specialist in radiation detectors and devices.
This strategic merger will enable the combined group to provide high-end detectors for nuclear market, to Business-to-Business customers, leveraging advanced technological capabilities.
The acquisition will further consolidate Exosens’ position in the field of nuclear instrumentation, in contributing to the development of the Small Modular Reactor commercial market.
Exosens, a high-tech company focused on providing mission and performance-critical amplification, detection and imaging technology, today announces the closing of the acquisition of UK-based company Centronic, a specialist developer and manufacturer of radiation detectors and devices.
By welcoming Centronic, Exosens will provide unique high-end detectors for nuclear market to their Business-to-Business customers through mastering of component manufacturing, a large geographical reach and advanced technological capabilities.
“With the acquisition of Centronic, we will consolidate our position in nuclear instrumentation to create a European leader. It will allow Exosens to offer the best advanced monitoring solutions to contribute to the development of the Small Modular Reactor commercial market. Exosens continues to deploy its accretive bolt-on strategy by acquisition of skilled companies to accelerate growth,”
commented Jérôme Cerisier, CEO of Exosens.
Centronic, based in UK with 87 employees, is a well-established technology leader in the field of radiation sensors solutions for photonic & ionising radiation including Gas-Filled detectors, Silicon Photodiodes, Geiger-Müller tubes and Coil Wound detectors, having a strong position in the worldwide high-end markets, such as nuclear.
“Created in 1945, Centronic has a strong background in developing high performance detectors for nuclear, aerospace and industrial markets. We’re very pleased to join Exosens and this transaction will allow us to build on that legacy, accelerate our growth and strengthen our product offer by R&D joint developments.” stated Neil Foreman, Executive Chairman of Centronic.
The transaction has been finalized. Terms of the transaction are not being disclosed.
